.Pharmacolibrary.Drugs.S_SensoryOrgans.S01L_OcularVascularDisorderAgents.S01LA06_Brolucizumab.Brolucizumab .Pharmacolibrary.Drugs.S_SensoryOrgans.S01L_OcularVascularDisorderAgents.S01LA06_Brolucizumab.Brolucizumab| name: | Brolucizumab |
| ATC code: | S01LA06 | route: | intravitreal |
| n-compartments | 1 |
Brolucizumab is a humanized single-chain antibody fragment (scFv) that targets vascular endothelial growth factor A (VEGF-A). It is used for the treatment of neovascular (wet) age-related macular degeneration (AMD) and is administered by intravitreal injection. Brolucizumab is approved and in clinical use.
Pharmacokinetic parameters reported for adult patients with neovascular (wet) age-related macular degeneration, receiving intravitreal injection of brolucizumab at the recommended clinical dose.
Nagaoka, K, et al., & Aizawa, K (2025). Comparative Pharmacokinetic Analysis of Aflibercept and Brolucizumab in Human Aqueous Humor Using Nano-Surface and Molecular-Orientation Limited Proteolysis. International journal of molecular sciences 26(2) –. DOI:10.3390/ijms26020556 PUBMED:https://pubmed.ncbi.nlm.nih.gov/39859273